Cover Image
市場調查報告書

皮膚炎:開發平台分析

Dermatitis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 192551
出版日期 內容資訊 英文 445 Pages
訂單完成後即時交付
價格
Back to Top
皮膚炎:開發平台分析 Dermatitis - Pipeline Review, H2 2015
出版日期: 2015年12月30日 內容資訊: 英文 445 Pages
簡介

本報告提供皮膚炎治療藥的開發情形的相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等。

簡介

  • 皮膚炎概要

治療藥的開發

  • 皮膚炎:企業開發中的治療藥
  • 皮膚炎:大學/機關研究中的治療藥
  • 皮膚炎:開發中產品概況
  • 皮膚炎:企業開發中的產品
  • 皮膚炎:大學/機關研究中的產品
  • 皮膚炎的治療藥的開發企業
  • 皮膚炎:治療藥的評估

藥物簡介

  • 皮膚炎:最近的開發平台趨勢
  • 皮膚炎:暫停中的計劃
  • 皮膚炎:開發中止的產品
  • 皮膚炎:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7067IDB

Summary

Global Markets Direct's, 'Dermatitis - Pipeline Review, H2 2015', provides an overview of the Dermatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dermatitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Dermatitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dermatitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dermatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Dermatitis Overview
  • Therapeutics Development
  • Dermatitis - Therapeutics under Development by Companies
  • Dermatitis - Therapeutics under Investigation by Universities/Institutes
  • Dermatitis - Pipeline Products Glance
  • Dermatitis - Products under Development by Companies
  • Dermatitis - Products under Investigation by Universities/Institutes
  • Dermatitis - Companies Involved in Therapeutics Development
  • Dermatitis - Therapeutics Assessment
  • Drug Profiles
  • Dermatitis - Recent Pipeline Updates
  • Dermatitis - Dormant Projects
  • Dermatitis - Discontinued Products
  • Dermatitis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Dermatitis, H2 2015
  • Number of Products under Development for Dermatitis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Dermatitis - Pipeline by 3SBio Inc., H2 2015
  • Dermatitis - Pipeline by Abeome Corporation, H2 2015
  • Dermatitis - Pipeline by Accolade Pharma LLC, H2 2015
  • Dermatitis - Pipeline by Aclaris Therapeutics, Inc., H2 2015
  • Dermatitis - Pipeline by AlbireoPharma, H2 2015
  • Dermatitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015
  • Dermatitis - Pipeline by Almirall, S.A., H2 2015
  • Dermatitis - Pipeline by Amgen Inc., H2 2015
  • Dermatitis - Pipeline by Amorepacific Corporation, H2 2015
  • Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015
  • Dermatitis - Pipeline by AnaMar AB, H2 2015
  • Dermatitis - Pipeline by AnaptysBio, Inc., H2 2015
  • Dermatitis - Pipeline by AnGes MG, Inc., H2 2015
  • Dermatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2015
  • Dermatitis - Pipeline by arGEN-X BV, H2 2015
  • Dermatitis - Pipeline by AskAt Inc., H2 2015
  • Dermatitis - Pipeline by Athenex, Inc., H2 2015
  • Dermatitis - Pipeline by Biomar Microbial Technologies, H2 2015
  • Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H2 2015
  • Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2015
  • Dermatitis - Pipeline by Celgene Corporation, H2 2015
  • Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2015
  • Dermatitis - Pipeline by China Biologic Products, Inc., H2 2015
  • Dermatitis - Pipeline by ChironWells GmbH, H2 2015
  • Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015
  • Dermatitis - Pipeline by Convoy Therapeutics, Inc., H2 2015
  • Dermatitis - Pipeline by Creabilis SA, H2 2015
  • Dermatitis - Pipeline by Delenex Therapeutics AG, H2 2015
  • Dermatitis - Pipeline by Dermira Inc., H2 2015
  • Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2015
  • Dermatitis - Pipeline by Eisai Co., Ltd., H2 2015
  • Dermatitis - Pipeline by Eli Lilly and Company, H2 2015
  • Dermatitis - Pipeline by EpiPharm AG, H2 2015
  • Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Dermatitis - Pipeline by FAES Farma SA, H2 2015
  • Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
  • Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2015
  • Dermatitis - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
  • Dermatitis - Pipeline by GlycaNova Norway AS, H2 2015
  • Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015
  • Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H2 2015
  • Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
  • Dermatitis - Pipeline by Hapten Sciences, Inc., H2 2015
  • Dermatitis - Pipeline by Herantis Pharma Plc, H2 2015
  • Dermatitis - Pipeline by iCo Therapeutics Inc., H2 2015
  • Dermatitis - Pipeline by ILiAD Biotechnologies, LLC, H2 2015
  • Dermatitis - Pipeline by IMMD Inc., H2 2015
  • Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H2 2015
  • Dermatitis - Pipeline by Immune Response BioPharma, Inc., H2 2015
  • Dermatitis - Pipeline by Inflamalps SA, H2 2015
  • Dermatitis - Pipeline by Japan Tobacco Inc., H2 2015
  • Dermatitis - Pipeline by Johnson & Johnson, H2 2015
  • Dermatitis - Pipeline by K-Stemcell Co., Ltd., H2 2015
  • Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2015
  • Dermatitis - Pipeline by LEO Pharma A/S, H2 2015
  • Dermatitis - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
  • Dermatitis - Pipeline by Madam Therapeutics B.V., H2 2015
  • Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2015
  • Dermatitis - Pipeline by Maruho Co., Ltd., H2 2015
  • Dermatitis - Pipeline by MedImmune, LLC, H2 2015
  • Dermatitis - Pipeline by Merck & Co., Inc., H2 2015
  • Dermatitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
  • Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2015
  • Dermatitis - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2015
  • Dermatitis - Pipeline by Novartis AG, H2 2015
  • Dermatitis - Pipeline by Nuvo Research Inc., H2 2015
  • Dermatitis - Pipeline by Orbis Biosciences, Inc., H2 2015
  • Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
  • Dermatitis - Pipeline by Oxagen Limited, H2 2015
  • Dermatitis - Pipeline by Pfizer Inc., H2 2015
  • Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2015
  • Dermatitis - Pipeline by Pharmedartis GmbH, H2 2015
  • Dermatitis - Pipeline by Phosphagenics Limited, H2 2015
  • Dermatitis - Pipeline by ProCertus BioPharm Inc., H2 2015
  • Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015
  • Dermatitis - Pipeline by Reata Pharmaceuticals, Inc., H2 2015
  • Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
  • Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2015
  • Dermatitis - Pipeline by SK Chemicals Co., Ltd., H2 2015
  • Dermatitis - Pipeline by Spherium Biomed S.L., H2 2015
  • Dermatitis - Pipeline by Stemnion, Inc, H2 2015
  • Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2015
  • Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015
  • Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
  • Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2015
  • Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
  • Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015
  • Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
  • Dermatitis - Pipeline by Vicore Pharma AB, H2 2015
  • Dermatitis - Pipeline by Vida Therapeutics Inc., H2 2015
  • Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015
  • Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015
  • Dermatitis - Pipeline by Welichem Biotech Inc., H2 2015
  • Dermatitis - Pipeline by XBiotech USA, Inc., H2 2015
  • Dermatitis - Pipeline by Xencor, Inc., H2 2015
  • Dermatitis - Pipeline by Ziarco Pharma Ltd, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Dermatitis Therapeutics - Recent Pipeline Updates, H2 2015
  • Dermatitis - Dormant Projects, H2 2015
  • Dermatitis - Dormant Projects (Contd..1), H2 2015
  • Dermatitis - Dormant Projects (Contd..2), H2 2015
  • Dermatitis - Dormant Projects (Contd..3), H2 2015
  • Dermatitis - Dormant Projects (Contd..4), H2 2015
  • Dermatitis - Dormant Projects (Contd..5), H2 2015
  • Dermatitis - Dormant Projects (Contd..6), H2 2015
  • Dermatitis - Dormant Projects (Contd..7), H2 2015
  • Dermatitis - Dormant Projects (Contd..8), H2 2015
  • Dermatitis - Dormant Projects (Contd..9), H2 2015
  • Dermatitis - Dormant Projects (Contd..10), H2 2015
  • Dermatitis - Dormant Projects (Contd..11), H2 2015
  • Dermatitis - Dormant Projects (Contd..12), H2 2015
  • Dermatitis - Dormant Projects (Contd..13), H2 2015
  • Dermatitis - Discontinued Products, H2 2015
  • Dermatitis - Discontinued Products (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for Dermatitis, H2 2015
  • Number of Products under Development for Dermatitis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top